NervGen Pharma Corp. (NGENF)
NervGen Pharma Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $3.95, down 2.47% on the session, giving a market capitalisation of $312.9M. On trailing twelve-month figures it carries a trailing P/E of -22.69, a net margin of 0.0%. Its beta of 0.76 implies it has historically moved less than the broad market.
NervGen Pharma Corp., including its affiliated entities, is focused on discovering, advancing, and bringing to market pharmaceutical solutions designed to address medical conditions arising from damage to the nervous system. Their primary experimental compound, NVG-291, is currently undergoing Phase 1 clinical trials to assess its potential effectiveness for spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company also maintains a licensing partnership with Case Western Reserve University, enabling them to research, further develop, and commercialize a patented technology that shows therapeutic promise for SCI and other conditions linked to nerve damage. Established in 2017, NervGen Pharma Corp. operates from its headquarters in Vancouver, Canada.
NervGen Pharma Corp. is most often compared with the following Healthcare names: